Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration

This is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular age-related macular degeneration.

Inclusion Criteria: 1. Written informed consent and ability to comply with the study protocol. 2. Male or female, aged 50-85 years. 3. Active subfoveal MNV secondary to nAMD requiring anti-VEGF treatment. 4. Demonstrated clinical response to aflibercept treatments in the study eye confirmed by the Reading Center; 5. Study-eye BCVA of 19-78 ETDRS letters. 6. Pseudophakic study eye. Exclusion Criteria: 1. Any ocular condition other than nAMD that may affect vision, study assessments, treatment safety, or interpretation of results. 2. Intraocular surgery or intraocular corticosteroid treatment within 4 weeks at screening. 3. Any ocular condition making the study eye unsuitable for subretinal injection. 4. Active ocular infection or inflammation, or a history of idiopathic or autoimmune uveitis. 5. Monocular status or non-study-eye BCVA \